Đáp ứng điều trị thiếu máu bằng erythropoietin alfa và một số yếu tố liên quan ở bệnh nhân bệnh thận mạn lọc máu chu kỳ tại Bệnh viện Đồng Nai 2

Abstract

Anemia is a prevalent complication among patients with stage 5 chronic kidney disease (CKD) undergoing maintenance hemodialysis. This observational before–after follow-up study included 120 hemodialysis patients treated with erythropoietin alfa to evaluate changes in hematologic parameters and factors associated with achieving the hemoglobin target after 3 months. After treatment, hemoglobin increased from 9.90 ± 1.25 to 10.80 ± 1.28 g/dL (p < 0.001), and the proportion of patients achieving Hb ≥ 11 g/dL rose from 16.7% to 45.8%. Baseline CRP was 3.00 (5.00) mg/L, while ferritin and Transferrin saturation were 474.50 (336.77) ng/mL and 22.60 (14.30) %, respectively. In multivariate analysis, baseline albumin and achieving Kt/V ≥ 1.2 before and after 3 months were independently associated with attaining the hemoglobin target. In contrast, ferritin and CRP showed no clear independent association with treatment response. These findings suggest that dialysis adequacy and nutritional status play important roles in anemia control among maintenance hemodialysis patients.